Actively Recruiting
Study of CG-102-12C CAR-T Cell Therapy for Adults With Glypican-3 Positive Advanced Hepatocellular Carcinoma Who Have Had Previous Treatments
Led by Zhejiang University · Updated on 2026-01-22
12
Participants Needed
2
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating CG-102-12C, a type of autologous chimeric antigen receptor T-cell therapy, in adults with advanced hepatocellular carcinoma HCC that tests positive for glypican-3 GPC3. This exploratory, single-center study focuses on participants who have previously received systemic treatments that were ineffective or not tolerated. The goal is to assess safety, tolerability, dosing, anti-tumor effects, and how the drug behaves in the body. Participants will receive a single infusion of CG-102-12C in a dose-escalation design across three dose groups, with about 7 to 12 participants per group. The study is open-label and does not include a placebo group. The treatment phase examines different doses to identify the recommended dose and monitor immediate responses and side effects. During the study, participants will be closely monitored for dose-limiting toxicities within 28 days after infusion and treatment-emergent adverse events for up to 24 months. Researchers will assess tumor response, disease control, remission duration, progression-free and overall survival, and pharmacokinetic parameters over follow-up periods that may last up to five years. Participants will undergo lab tests, tumor evaluations by imaging, and other clinical assessments throughout the study period.
CONDITIONS
Brief Title
A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
Research Team
Q
Qi Zhang, Professor
F
Fan Yang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here